Header

UZH-Logo

Maintenance Infos

Rationally designed ruthenium complexes for 1- and 2-photon photodynamic therapy


Karges, Johannes; Kuang, Shi; Maschietto, Federica; Blacque, Olivier; Ciofini, Ilaria; Chao, Hui; Gasser, Gilles (2020). Rationally designed ruthenium complexes for 1- and 2-photon photodynamic therapy. Nature Communications, 11:3262.

Abstract

The use of photodynamic therapy (PDT) against cancer has received increasing attention over recent years. However, the application of the currently approved photosensitizers (PSs) is limited by their poor aqueous solubility, aggregation, photobleaching and slow clearance from the body. To overcome these limitations, there is a need for the development of new classes of PSs with ruthenium(II) polypyridine complexes currently gaining momentum. However, these compounds generally lack significant absorption in the biological spectral window, limiting their application to treat deep-seated or large tumors. To overcome this drawback, ruthenium(II) polypyridine complexes designed in silico with (E,E)-4,4 ' -bisstyryl-2,2 ' -bipyridine ligands show impressive 1- and 2-Photon absorption up to a magnitude higher than the ones published so far. While nontoxic in the dark, these compounds are phototoxic in various 2D monolayer cells, 3D multicellular tumor spheroids and are able to eradicate a multiresistant tumor inside a mouse model upon clinically relevant 1-Photon and 2-Photon excitation. p id=Par Photosensitizers that are stable in biological conditions with absorption in the biological spectral window are needed for photodynamic therapy. Here, the authors report on the development of a Ruthenium complex for 1 and 2-photon therapy to address these issues and demonstrate application in vivo.

Abstract

The use of photodynamic therapy (PDT) against cancer has received increasing attention over recent years. However, the application of the currently approved photosensitizers (PSs) is limited by their poor aqueous solubility, aggregation, photobleaching and slow clearance from the body. To overcome these limitations, there is a need for the development of new classes of PSs with ruthenium(II) polypyridine complexes currently gaining momentum. However, these compounds generally lack significant absorption in the biological spectral window, limiting their application to treat deep-seated or large tumors. To overcome this drawback, ruthenium(II) polypyridine complexes designed in silico with (E,E)-4,4 ' -bisstyryl-2,2 ' -bipyridine ligands show impressive 1- and 2-Photon absorption up to a magnitude higher than the ones published so far. While nontoxic in the dark, these compounds are phototoxic in various 2D monolayer cells, 3D multicellular tumor spheroids and are able to eradicate a multiresistant tumor inside a mouse model upon clinically relevant 1-Photon and 2-Photon excitation. p id=Par Photosensitizers that are stable in biological conditions with absorption in the biological spectral window are needed for photodynamic therapy. Here, the authors report on the development of a Ruthenium complex for 1 and 2-photon therapy to address these issues and demonstrate application in vivo.

Statistics

Citations

Dimensions.ai Metrics
175 citations in Web of Science®
170 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

27 downloads since deposited on 26 Oct 2020
7 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:07 Faculty of Science > Department of Chemistry
Dewey Decimal Classification:540 Chemistry
Scopus Subject Areas:Physical Sciences > General Chemistry
Life Sciences > General Biochemistry, Genetics and Molecular Biology
Physical Sciences > General Physics and Astronomy
Uncontrolled Keywords:General Biochemistry, Genetics and Molecular Biology, General Physics and Astronomy, General Chemistry
Language:English
Date:1 December 2020
Deposited On:26 Oct 2020 11:28
Last Modified:23 Jun 2024 01:44
Publisher:Nature Publishing Group
ISSN:2041-1723
OA Status:Gold
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1038/s41467-020-16993-0
  • Content: Published Version
  • Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)